Features

The biotech industry stands at a crossroads. The interplay between innovation, policy changes, and pricing challenges will shape the future of biotech, influencing how companies navigate funding, research, and product development.

How are small-molecule drugs faring in new drug approvals by FDA thus far in 2025? Where does the industry stand now and comparative to recent trends? DCAT Value Chain Insights looks at the products and companies.

FDA has introduced a new pilot program to prioritize abbreviated new drug applications for generic drugs that use US-based manufacturing and testing, the latest in a series of moves by the Administration to incentivize US-based manufacturing.

Antibody drug conjugates (ADCs) are a growing modality in the oncology drug market. Bispecific ADCs are an emerging subset of ADCs with several investigational drug candidates advancing. The latest developments in the ADC drug market.

For the bio/pharma industry, it has been again another active week on the US policy front, with additional moves relating to tariffs, the federal government shutdown, and drug pricing. What is the latest?

Takeda announced this week it is exiting the cell therapy market, and FDA issues three draft guidances to facilitate development of cell & gene therapies. How is the advanced therapies market faring thus far in 2025?

As the industry enters the fourth quarter, how do new drug approvals by FDA’s Center for Drug Evaluation and Research stand now and comparative to recent trends? What is the mix between small molecules and biologics? DCAT Value Chain Insights looks at the products and companies.

With its pending $7.3-billion deal to acquire the bio/pharmaceutical company, Metsera, Pfizer is making a strong play in the obesity drug market. What are the assets that Pfizer will be acquiring, and how do they stack up against the other notable contenders in the obesity drug market?

The US Supreme Court is set to hear oral arguments on November 5, 2025, in a case examining the legal authority of the current Administration to impose tariffs under the International Emergency Economic Powers Act, which was used to impose reciprocal tariffs on a country-by-country basis. What may be next?

How does advanced manufacturing in pharma, such as continuous manufacturing, AI-enabled manufacturing, or distributed manufacturing factor into the current investment activity and policy moves to increase US-based pharma manufacturing? DCAT Value Chain Insights takes an inside look at the latest developments.